• Enables testing of populations with an estimated 100% seroprevalence
• Designed to enable vaccine research
• 2-phase orthogonal testing method for detection of SARS-CoV-2 IgG antibodies
R&D Systems is a premier brand of Bio-Techne Corporation, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne’s brand, R&D Systems, provides the tools needed for scale up, validation, and continuous supply of the Kantaro Biosciences COVID-SeroIndex ELISA.
Kantaro Biosciences ("Kantaro"), a Mount Sinai Health System venture, is dedicated to ensuring that diagnostic tests for critical health challenges are accessible to all. The company provides academically rigorous, validated and results-driven diagnostics to advance the wellbeing of people, communities and society. Kantaro specializes in the rapid scaleup of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. The company is majority owned and controlled by Mount Sinai.
For more information, visit www.kantarobio.com.